John Adams

Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Pharmaceuticals, Infectious Diseases

Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.Pharmaceuticals, Infectious Diseases

Competitive Advantages: Retains significantly high viablility, Effective for plasmodium research, Application in whole-parasite vaccine Key role in liver stage research. Described herein are compositions and methods to cryopre­serve sporozoites. In some aspects, the method can include the step of placing harvested salivary glands containing sporozoites into an insect-based medium.We have developed a novel method to allow the harvested sporozoites to be cryopreserved and thawed effectively. This method will allow the sporozoites to retain a significantly high viability and infectivity at 70% or greater, which is a substantial improvement when compared to the current standard. Retaining such a high viability and sporozoite functionality overcomes the limitations presented previously in Plasmodium sporozoite and liver stage research. Sporozoites and other parasitic cells prepared aseptically in this manner are suitable for clinical use as a whole-parasite vaccine and pre-clinical discovery research studies.